## Novel Perspectives to Optimize Practice Management

Priya Bansal, MD 6-1-24

### **Learning Objective**

Upon completion of this activity, participants should be able to identify opportunities for growth in their practices and formulate a plan to implement 1 those those opportunities.






## How to Optimize Workflow?

- Build the website and integrate flow
  - Calendar appts linking to the software
  - Link to fill out paperwork
  - EMR connection for paperwork
  - Insurance Listing for patients and insurance input to verify in advance
  - Text messaging for reminders/confirmation of appts.



#### At the Office

- Check in Kiosk/Ipad
- Precheck insurance verification
- Separate check in and check out desk
- Staffing- Prior auth/messages/ideal staffing number
- Training –one on one and then running it with the team





- Create paperwork with insurance and prior auths in mind.
- Failed meds circle the ones you've failed in categories
- QOL measures- ACT, UAS 7, POEM/EASI, etc.
- Biologic/immunodeficiency/H AE sheets with prompts printed.
- Make the patient a partner-
  - Have patients bring in the med lists from the pharmacy.
  - Have patients journal or do an app to capture flare data

#### Paper

### **EMR**

- Partner with the vendor to work on workflow and minimize clicks
- Look for partnerships for an immunotherapy module
- Work with vendors working on utilizing A/I
- Multiple ways to use A/I smart prompts, sound and dictation technology, prior authorization optimization
- Use the EMR to message and reach out to specific patient populations
- Program via smart phrases, macros and order sets as much as possible.

### Know your Billing and Coding


If employed- Learn about RVUs (relative value units)- what RVUs are covered by the institution you work at and who gets credit for those.

How many RVUs are expected in your position and what is the RVU dollar per unit?

| CPT<br>Code | Description   | 2023 RVUs | 2023 National<br>Payment Amt.<br>(CF of<br>\$33.8872) | Percent<br>Change 2023<br>to 2024 | 2024 RVUs | 2024 National Payment Amt. (CF of \$32.7442) |
|-------------|---|-----------|---|-----------------------------------|-----------|--|
| 95004       | Percutaneous allergy skin tests                       | 0.12      | \$4.07  | -11.43%                           | 0.11      | \$3.60                                       |
| 95012       | Nitric oxide expired gas determination                | 0.56      | \$18.98   | -1.65%                            | 0.57      | \$18.66                                      |
| 95017       | Venom testing; percutaneous and intradermal           | 0.26      | \$8.81  | -3.37%                            | 0.26      | \$8.51                                       |
| 95018       | Drug/biological testing; percutaneous and intradermal | 0.60      | \$20.33   | -3.37%                            | 0.60      | \$19.65                                      |
| 95024       | Allergy test, intradermal                             | 0.24      | \$8.13  | -3.37%                            | 0.24      | \$7.86                                       |
| 95027       | Allergy test, intradermal for airborne                | 0.15      | \$5.08  | -3.37%                            | 0.15      | \$4.91                                       |
| 95070       | Inhalation bronchial challenge testing                | 1.03      | \$34.90   | -1.50%                            | 1.05      | \$34.38                                      |
| 95076       | Ingestion challenge test; first 120 minutes           | 3.60      | \$121.99  | -0.69%                            | 3.70      | \$121.15                                     |
| 95079       | Ingestion challenge test; each additional hour        | 2.51      | \$85.06   | -1.45%                            | 2.56      | \$83.83                                      |
| 95115       | Immunotherapy, one injection                          | 0.30      | \$10.17   | -0.15%                            | 0.31      | \$10.15                                      |
| 95117       | Immunotherapy, two or more injections                 | 0.35      | \$11.86   | 2.15%                             | 0.37      | \$12.12                                      |

| CPT<br>Code    | Description Antigen therapy services (5 venums)   | 2023 RVUs | 2023 National Payment Amt. (CF of \$33.8872) | Percent<br>Change 2023<br>to 2024 | 2024 RVUs | 2024 National<br>Payment Amt.<br>(CF of<br>\$32.7442) |  |
|----------------|---|-----------|--|-----------------------------------|-----------|---|--|
| 95148          | Antigen therapy services (4 venoms)   | 2.60      | \$88.11                                      | 7.78%                             | 2.90      | \$94.96   |  |
| 95149          | Antigen therapy services (5 venoms)   | 3.44      | \$116.57                                     | 8.42%                             | 3.86      | \$126.39  |  |
| 95165          | of preparation and provision of antigens<br>for allergen immunotherapy; single or<br>multiple antigens (specify number of<br>doses)   | 0.45      | \$15.25                                      | -5.52%                            | 0.44      | \$14.41   |  |
| 95170          | other arthropod (specify number of doses)  Kapia desensitization procedure, each  | 0.34      | \$11.52                                      | -6.21%                            | 0.33      | \$10.81   |  |
| 95180<br>94010 | Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation                          | 0.80      | \$137.92<br>\$27.11                          | -1.47%<br>-0.96%                  | 0.82      | \$135.89<br>\$26.85                                   |  |
| 94014          | per 30-day; includes education,<br>transmission of spirometric tracing, data<br>capture, analysis of transmitted data,<br>periodic recalibration and review and<br>interpretation | 1.64      | \$55.58                                      | -1.02%                            | 1.68      | \$55.01   |  |
| 94060          | Bronchodialtion responsiveness, spirometry pre and post bronchodilator admin.   | 1.15      | \$38.97                                      | -1.69%                            | 1.17      | \$38.31   |  |

| CPT<br>Code    | Description  | 2023 RVUs    | 2023 National Payment Amt. (CF of \$33.8872) | Percent<br>Change 2023<br>to 2024 | 2024 RVUs    | 20<br>Pag |
|----------------|--|--------------|--|-----------------------------------|--------------|-----------|
| 04070          | Bronchospasm provocation eval. multiple spirometric determinations, with | 1 02         | \$61.67                                      | 0.240/                            | 1 90         |           |
| 94070<br>96401 | Anti-neoplastic injection  | 1.82<br>2.17 | \$61.67<br>\$73.54                           | 0.34%<br>-4.26%                   | 1.89<br>2.15 |           |
| 96372<br>99202 | Therapeutic injection Office/outpatient visit new                        | 0.42<br>2.15 | \$14.23<br>\$72.86                           | -1.07%<br>-2.47%                  | 0.43<br>2.17 |           |
| 99203<br>99204 | Office/outpatient visit new Office/outpatient visit new                  | 3.33<br>4.94 | \$112.84<br>\$167.40                         | -2.79%<br>-1.81%                  | 3.35<br>5.02 |           |
| 99205<br>99211 | Office/outpatient visit new Office/outpatient visit est                  | 6.52<br>0.69 | \$220.94<br>\$23.38                          | -1.89%<br>-1.97%                  | 6.62<br>0.70 |           |
| 99212<br>99213 | Office/outpatient visit est Office/outpatient visit est                  | 1.68<br>2.68 | \$56.93<br>\$90.82                           | -2.22%<br>-1.57%                  | 1.70<br>2.73 |           |
| 99214<br>99215 | Office/outpatient visit est Office/outpatient visit est                  | 3.79<br>5.31 | \$128.43<br>\$179.94                         | -1.84%<br>-1.37%                  | 3.85<br>5.42 |           |



| CODE  | DESCRIPTION   | MEDICARE AND MEDICAID MUE<br>(PER DATE OF SERVICE) |
|-------|---|--|
| 95004 | Percutaneous tests (scratch, puncture, prick)       | 80   |
| 95012 | Expired Nitric Oxide                                | 2  |
| 95017 | Venom skin testing                                  | 27   |
| 95018 | Skin testing for drugs and biologicals              | 19   |
| 95024 | Intracutaneous tests/allergenic extracts            | 40   |
| 95027 | Intracutaneous sequential and incremental           | 90   |
| 95028 | Intracutaneous/allergenic extracts/delayed reaction | 30   |
| 95044 | Patch test  | 80   |
| 95180 | Rapid desensitization/each hour                     | 6  |

| 95076 | Ingestion challenge/initial 120 minutes   | 1  |
|-------|---|----|
| 95079 | Ingestion challenge/each additional hour  | 2  |
| 95144 | Allergy immunotherapy /single dose vials  | 30 |
| 95145 | Venom immunotherapy/1 venom               | 10 |
| 95146 | Venom immunotherapy/2 venoms              | 10 |
| 95147 | Venom immunotherapy/3 venoms              | 10 |
| 95148 | Venom immunotherapy/4 venoms              | 10 |
| 95149 | Venom immunotherapy/5 venoms              | 10 |
| 95165 | Allergen immunotherapy/multi-dose vials   | 30 |
| 95170 | Allergen immunotherapy/whole body extract | 10 |



• 31-year-old commercially insured patient comes to the clinic for an amoxicillin drug challenge. She had a history of hives and shortness of breath 6 years ago along amoxicillin in the past that required epinephrine use.

# Do an office visit the same day as the challenge?

Do drug skin testing the same day as the challenge?

If testing, do we bill for the controls- histamine and saline?

#### What did we do?

- We decided to skin test the patient via prickhistamine, saline, amoxicillin and pre-pen. They were negative.
- We then did intradermals to saline, amoxicillin and pre-pen which were also negative.
- We then proceeded to do a 2 step drug challenge which started at 9:12 AM and ended at 10:50 AM.
- An office follow up visit was not completed.
- What codes do we use to bill this patient?



## Time Based Coding

- 99202 15-29 minutes of total time is spent on the date of the encounter.
- 99203 30-44 minutes
- 99204 45-59 minutes
- · 99205 60-74 minutes
- For services 75 minutes or longer, see Prolonged Services
- 99212 10-19 minutes
- · 99213 20-29 minutes
- · 99214 30-39 minutes
- · 99215 40-54 minutes
- For services 55 minutes or longer, see Prolonged Services



## Time Based Coding Considerations

- Reviewing notes
- Talking to consultants
- Reviewing procedures- skin tests, spirometries, etc
- Reviewing labs
- Counseling family members
- Other care coordination



|                |  | Elements of Medical Decision Making  |   |  |  |  |  |
|----------------|--|--|---|--|--|--|--|
| Code           | Level of MDM<br>(Based on 2 out of 3<br>Elements of MDM) | Number and Complexity<br>of Problems Addressed   | Risk of Complications and/or<br>Morbidity or Mortality of<br>Patient Management   |  |  |  |  |
| 99211          | N/A  | N/A  | N/A   | N/A  |  |  |  |
| 99202<br>99212 | Straightforward  | Minimal  • 1 self-limited or minor problem   | Minimal or none   | Minimal risk of morbidity from additional diagnostic testing or treatment  |  |  |  |
| 99203<br>99213 | Low  | Low • 2 or more self-limited or minor problems or • 1 stable chronic illness or • 1 acute, uncomplicated illness or injury   | Limited (Must meet the requirements of at least 1 of the 2 categories) Category 1: Tests and documents Any combination of 2 from the following: • Review of prior external note(s) from each unique source* • Review of the result(s) of each unique test* • Ordering of each unique test* or Category 2: Assessment requiring independent historian(s) (For the categories of independent interpretation of tests and discussion of management or test interpretation, see moderate or high)   | Low risk of morbidity from additional diagnostic testing or treatment  |  |  |  |
| 99204<br>99214 | Moderate   | Moderate  1 or more chronic illnesses with exacerbation, progression, or side effects of treatment  or  2 or more stable chronic illnesses  or  1 undiagnosed new problem with uncertain prognosis  or  1 acute illness with systemic symptoms  or  1 acute complicated injury | Moderate  (Must meet the requirements of at least 1 out of 3 categories)  Category 1: Tests, documents, or independent historian(s)  Any combination of 3 from the following:  Review of prior external note(s) from each unique source*  Review of the result(s) of each unique test*  Ordering of each unique test*  Assessment requiring independent historian(s)  or  Category 2: Independent interpretation of tests  Independent interpretation of a test performed by another physician/other qualified health care professional (not separately reported)  or  Category 3: Discussion of management or test interpretation  Discussion of management or test interpretation with external physician/other qualified health care professional/appropriate source (not separately reported)     | Moderate risk of morbidity from additional diagnostic testing or treatment  Examples only:  Prescription drug management  Decision regarding minor surgery with identified patient or procedure risk factors  Decision regarding elective major surgery without identified patient or procedure risk factors  Diagnosis or treatment significantly limited by social determinants of health                          |  |  |  |
| 99205<br>99215 | High   | High     1 or more chronic illnesses with severe exacerbation, progression, or side effects of treatment     or     1 acute or chronic illness or injury that poses a threat to life or bodily function  | Extensive (Must meet the requirements of at least 2 out of 3 categories) Category 1: Tests, documents, or independent historian(s) Any combination of 3 from the following: • Review of prior external note(s) from each unique source*; • Review of the result(s) of each unique test*; • Ordering of each unique test*; • Assessment requiring independent historian(s) or Category 2: Independent interpretation of tests • Independent interpretation of a test performed by another physician/other qualified health care professional (not separately reported); or Category 3: Discussion of management or test interpretation • Discussion of management or test interpretation with external physician/other qualified health care professional/appropriate source (not separately reported) | High risk of morbidity from additional diagnostic testing or treatment Examples only:  • Drug therapy requiring intensive monitoring for toxicity  • Decision regarding elective major surgery with identified patient or procedure risk factors  • Decision regarding emergency major surgery  • Decision regarding hospitalization  • Decision not to resuscitate or to de-escalate care because of poor prognosis |  |  |  |

#### Case 2

- Pediatric patient presents with a history of anaphylaxis to peanuts, asthma and allergic rhinitis. Patient's parents are divorced and mom advises you that data needs to be communicated to dad as well.
- Skin testing was done via prick to 16 antigens.
- Spirometry pre-post was done using patient's own inhaler for rescue
- FENO was completed as well.
- Patient was counseled about diseases and medications taught including rescue and maintenance inhaler.
- Skin testing took 30 minutes for application and interpretation.
- Visit was 65 minutes in addition to that.



# How would we code this visit?

# Are you coding for everything you are doing in the clinic?



#### Case 3

 Patient wishes to start allergy shots. Your first build that you mix through the green, blue and yellow bottles is 27 Units for the pollen bottle and 27 units for the Dust Mite bottle.

# How can I mix those bottles properly for billing?



What if I had another bottle with 27 Units of Cat?



Create opportunities to be the expert and expand your practice!

- Social media is a great resource.
   Use it to expand your brand and educate
  - https://youtu.be/wD6PRsqbia8
  - https://www.tiktok.com/@allerg ygalmd/video/70089008699828 99462
  - Have fun!

# Expand your product line

- OIT
- Remote patient monitoring
- Patch Testing
- Clincal Research
- Nasal Endoscopy
- Food and Drug Challenges
- Cluster and Rapid Desensitization Immunotherapy
- Biologics (Biologic Contract)

### Plan, Practice, Execute

